Last Update: Jan 14, 2025 Regulatory Post-Marketing Surveillance (rPMS) Study for Brolucizumab(Beovu ® Injection, Beovu ®Prefilled Syringe) ClinicalTrials.gov Identifier: [NCT04985487](https://clinicaltrials.gov/ct2/show/NCT04985487) Novartis Reference Number:CRTH258AKR01 [See if you Pre-qualify](#trial-eligibility "See if you Pre-qualify") All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation. ## Study Description This study is an open-label, multicenter, single-arm, observational post-marketing surveillance. The investigators will collect safety information and evaluate effectiveness in patients who are prescribed Beovu ® Injection, Beovu ®Prefilled Syringe (brolucizumab) in the approved indication after receiving informed consent over a period of 12 weeks. In addition, longer-term data (24 weeks, optionally 36 weeks) will be collected. Condition Neovascular Age-related Macular Degeneration Overall Status Recruiting Number of Participants3000 Start Date Aug 18, 2021 Completion Date Jun 14, 2026 Gender All Age(s) 18 Years - 100 Years (Adult, Older Adult) ## Interventions Other ### brolucizumab Prospective observational study. There is no treatment allocation. Patients administered brolucizumab, that have started before inclusion of the patient into the study will be enrolled. ## Eligibility Criteria Inclusion Criteria: 1\. Patients aged ≥18 years with nAMD that are prescribed with Brolucizumab as per approved local product information 2\. Patients who consent to participate in the study after the purpose and nature of the study have clearly explained to them (written informed consent) Exclusion Criteria: 1\. Contraindications as per local prescribing information 1) Hypersensitivity to the active substance or to any of the excipients. 2) Active or suspected ocular or periocular infection. 3) Active intraocular inflammation. 2\. Patients participating in other investigational drug trial South Korea #### Novartis Investigative Site Recruiting Jeju City,63206,South Korea #### Novartis Investigative Site Recruiting Taegu,41944,South Korea #### Novartis Investigative Site Recruiting Seoul,07441,South Korea #### Novartis Investigative Site Recruiting Seoul,07301,South Korea #### Novartis Investigative Site Recruiting Seoul,06351,South Korea #### Novartis Investigative Site Recruiting Seoul,06273,South Korea #### Novartis Investigative Site Recruiting Seoul,05368,South Korea #### Novartis Investigative Site Recruiting Seoul,04763,South Korea #### Novartis Investigative Site Recruiting Seoul,04401,South Korea #### Novartis Investigative Site Recruiting Seoul,03722,South Korea #### Novartis Investigative Site Recruiting Seoul,03080,South Korea #### Novartis Investigative Site Recruiting Seoul,02841,South Korea #### Novartis Investigative Site Recruiting Seoul,01000,South Korea #### Novartis Investigative Site Recruiting Pusan,614 735,South Korea #### Novartis Investigative Site Recruiting Daegu,Dalseo Gu,42602,South Korea #### Novartis Investigative Site Recruiting Incheon,22332,South Korea #### Novartis Investigative Site Recruiting Gwangju,61932,South Korea #### Novartis Investigative Site Recruiting Gwangju,61489,South Korea #### Novartis Investigative Site Recruiting Daegu,705703,South Korea #### Novartis Investigative Site Recruiting Daegu,705 718,South Korea #### Novartis Investigative Site Recruiting Busan,49241,South Korea #### Novartis Investigative Site Recruiting Busan,48064,South Korea #### Novartis Investigative Site Recruiting Busan,47524,South Korea #### Novartis Investigative Site Recruiting Daejeon,Korea,35015,South Korea #### Novartis Investigative Site Recruiting Iksan Si,Jeonlabuk Do,570-711,South Korea #### Novartis Investigative Site Recruiting Suwon,Gyeonggi-do,16499,South Korea #### Novartis Investigative Site Recruiting Guri-si,Gyeonggi-do,471-701,South Korea #### Novartis Investigative Site Recruiting Goyang-si,Gyeonggi-do,10380,South Korea ## Worldwide Contacts If the location of your choosing does not feature any contact detail, please reach out using the information below. #### Novartis Pharmaceuticals Phone: [ +41613241111](tel:+41613241111) Email: